FDA Plays

[colorofmoney]

PDMI News..CORRECTION - Paradigm to Become Current With Financial Disclosure Reporting and
Update on Retimax(TM) FDA Application

SALT LAKE CITY, UT, Jun 09, 2010 (MARKETWIRE via COMTEX) -- In the news release,
"Paradigm to Become Current With Financial Disclosure Reporting and Update on
Retimax(TM) FDA Application," issued earlier today by Paradigm Medical
Industries, Inc. (PINKSHEETS: PDMI), we are advised by the company that the
second sentence of the second paragraph should read "On June 8, 2010, Paradigm
posted a Quarterly Report for the period ended September 30, 2009 on the Pink OTC
Markets." rather than "On June 8, 2010, Paradigm posted a Quarterly Report for
the period ended September 30, 2010 on the Pink OTC Markets." as originally
issued. Complete corrected text follows.

Paradigm to Become Current With Financial Disclosure Reporting and Update on
Retimax(TM) FDA Application

SALT LAKE CITY, UT -- June 8, 2010 -- Paradigm Medical Industries, Inc.
(PINKSHEETS: PDMI) announced today that it has begun the process of becoming and
remaining current with its financial and disclosure obligations on the Pink OTC
Markets. During most of 2009, due to limited working capital, Paradigm was unable
to remain current with its quarterly and annual reports. Paradigm recently
obtained some additional funding and, as a result, has begun to correct this
critical step concerning its responsibility to provide financial information to
its shareholders and the investment community.

On June 4, 2010, Paradigm posted a Quarterly Report for the period ended June 30,
2009 on the Pink OTC Markets. On June 8, 2010, Paradigm posted a Quarterly Report
for the period ended September 30, 2009 on the Pink OTC Markets. Paradigm is in
the process of completing a financial audit and preparing an Annual Report for
the fiscal year ended December 31, 2009.

"As Paradigm continues to rebuild itself, it is vital that its shareholders be
kept aware of the important steps that management has taken to complete this
process. With the recent financial assistance from an outside source, Paradigm
will overcome this obstacle just as it has many other obstacles the past year,"
said Stephen Davis, Paradigm's President and Chief Executive Officer.

Paradigm also has been advised by Costruzione Strumenti Oftalmici (CSO), its
Italian partner, that there was a delay in the filing of the 510(k) application
for the Retimax(TM) (Paramax) with the FDA. The application was submitted in May
2010 rather than in February 2010 as first disclosed. The Retimax(TM) has been
designed to perform innovative tests for the early screening and follow-up for
glaucoma, age related macular degeneration, vascular retinal degeneration, and
other pathologies related to the optic nerve disease.

"Although this information concerning the filing of the 510(k) application comes
as somewhat of a surprise, it does not lessen the considerable anticipation for
this new technology by Paradigm and its customers. Paradigm will make the
necessary adjustments in its marketing and sales efforts to reflect this change.
Paradigm understands CSO's decision to delay filing the 510(k) application until
it was completely prepared to submit it for FDA approval," added Mr. Davis.

About Paradigm Medical Industries, Inc.

Paradigm Medical Industries, Inc. is a medical device company that develops,
manufactures and distributes ophthalmic diagnostic instruments and related
products for early detection of glaucoma and other eye disorders. The Company's
primary objective is to capture a niche market within the glaucoma and ultrasound
microscopy fields. The Company markets its products to ophthalmologists,
optometrists, universities, and clinics throughout the United States and
internationally.

This press release contains statements that, if not verifiable historic fact, may
be viewed as forward-looking statements that could predict future events and
outcomes with respect to Paradigm and its business. The predictions embodied in
these statements will involve risk and uncertainties and, accordingly, actual
results may differ significantly from the results discussed or implied in such
forward-looking statements.

Contact:
Stephen L. Davis
President and Chief Executive Officer
801-977-8970
http://www.paradigm-medical.com




SOURCE: Paradigm Medical Industries, Inc.
http://www.paradigm-medical.com


Copyright 2010 Marketwire, Inc., All rights reserved.